A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Atul Pande Biography and Net Worth

Director of Karuna Therapeutics

Dr. Pande is a physician who qualified in medicine, and specialized in psychiatry, at the University of Lucknow in India. He obtained additional specialty training at Western University in Canada, and subsequently served on the faculty of the University of Michigan Medical School. Over nearly thirty years of his academic and industry career, Dr. Pande has been involved in the development of important central nervous system drugs while holding various senior roles in GlaxoSmithKline, Pfizer, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer’s and Parkinson’s diseases, and others.

Dr. Pande currently serves as Senior Advisor to PureTech Health; non-executive director of Autifony Therapeutics; lead independent director of Axovant Gene Therapies (NASDAQ:AXGT); scientific advisory to Cennerv Pharma; development consultant to various companies; and as President and CEO of Verity BioConsulting. Dr. Pande is a fellow of several professional societies, including the American Psychiatric Association. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.

What is Atul Pande's net worth?: The estimated net worth of Atul Pande is at least $824,575.00 as of September 1st, 2021. Dr. Pande owns 2,500 shares of Karuna Therapeutics stock worth more than $824,575 as of April 20th. This net worth estimate does not reflect any other assets that Dr. Pande may own. Learn More about Atul Pande's net worth.
How do I contact Atul Pande?: The corporate mailing address for Dr. Pande and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Atul Pande's contact information.
Has Atul Pande been buying or selling shares of Karuna Therapeutics?: Atul Pande has not been actively trading shares of Karuna Therapeutics during the last ninety days. Most recently, Atul Pande sold 2,500 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $110.80, for a transaction totalling $277,000.00. Learn More on Atul Pande's trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 104,119 shares worth more than $23,414,081.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 3/8/2024.

Atul Pande Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2022	Sell	2,500	$110.80	$277,000.00
1/3/2022	Sell	2,500	$130.44	$326,100.00
12/1/2021	Sell	2,500	$127.73	$319,325.00
10/1/2021	Sell	2,500	$120.72	$301,800.00
9/1/2021	Sell	2,500	$117.82	$294,550.00	2,500
8/2/2021	Sell	2,500	$114.17	$285,425.00
6/1/2021	Sell	2,500	$111.44	$278,600.00	2,500
5/3/2021	Sell	2,500	$110.61	$276,525.00	2,500
4/1/2021	Sell	2,500	$120.01	$300,025.00	2,500
2/1/2021	Sell	2,500	$100.00	$250,000.00	2,500
12/14/2020	Sell	5,714	$92.64	$529,344.96	5,714
11/12/2020	Sell	5,000	$96.84	$484,200.00
11/3/2020	Sell	5,000	$85.00	$425,000.00	5,000
9/16/2020	Sell	5,000	$85.00	$425,000.00	5,000
7/13/2020	Sell	5,000	$95.43	$477,150.00	5,000

Atul Pande Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $329.83

$329.83

50 Day Range

MA: $324.58

$313.97

$329.83

2 Week Range

Now: $329.83

$158.38

$329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad